Our multi-modality team player.
CiÄ¢¹½´«Ã½‘Ca therapy
Think CiÄ¢¹½´«Ã½‘Ca therapy.
Your responsibility in good hands.
Your professional world is changing constantly. You appreciate technologies that are continuously evolving and help you to provide your patients with even better therapy. We would like to support you by offering a comprehensive approach for citrate anticoagulation-based CKRT: CiÄ¢¹½´«Ã½‘Ca therapy.
At a time when healthcare professionals are increasingly involved in non-caregiving activities such as administration, treatment documentation and medication preparation, there is a growing need for reliable, one-stop solutions which decrease the strain on the ICU staff.
Ä¢¹½´«Ã½ is the first provider to offer a complete range of CiÄ¢¹½´«Ã½‘Ca therapy products from a single source, supporting healthcare professionals to focus on the essential: patient care.
Regional citrate anticoagulation enables patient treatment with less bleeding complications and less filter clotting compared to heparin CKRT.1Ä¢¹½´«Ã½‘3ÌýAs one option to implement regional citrate anticoagulation, CiÄ¢¹½´«Ã½‘Ca therapy is an effective and reliable alternative to heparin4Ä¢¹½´«Ã½‘11Ìýand lets your ICU staff focus more on the patient and less on handling issues.5,11
Participate in our experience: Ä¢¹½´«Ã½ was the first to offer a completely machine integrated CiÄ¢¹½´«Ã½‘Ca regional citrate anticoagulation. Healthcare professionals in more than 30 countries have already gained experience with CiÄ¢¹½´«Ã½‘Ca therapy and appreciate its reliable and easy application in clinical routines.5,6
Our proven citrate protocol is integrated in theÌýmultiFiltratePROÌýand reflected in all our CiÄ¢¹½´«Ã½‘Ca products.
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">In-center HD</span></h3>
Ìý
Think reliable.
Think CiÄ¢¹½´«Ã½‘Ca therapy.
Your question
What is the advantage of CiÄ¢¹½´«Ã½‘Ca therapy over standard heparin treatment?
Ìý
Ìý
Ìý
Ìý
Ìý
Our answer
Citrate anticoagulation-based CKRT enables excellent patient treatment with fewer bleeding complications and less filter clotting compared to heparin.1,3,12,13ÌýCiÄ¢¹½´«Ã½‘Ca regional anticoagulation is an effective and reliable alternative to heparin:
- Proven citrate protocol5Ä¢¹½´«Ã½‘8
- Enabling adherence to KDIGO AKI guideline2
- Low associated bleeding risk5,7,8
- Long filter patency4,6,8,10
Think smart.
Think CiÄ¢¹½´«Ã½‘Ca therapy.
Your question
How can CiÄ¢¹½´«Ã½‘Ca therapy give me moreÌýplannability and reduce my workload?
Ìý
Ìý
Ìý
Ìý
Our answer
Compared to heparin anticoagulation, CiÄ¢¹½´«Ã½‘Ca therapy reduces the number of nurse interventions, and facilitates efficient work planning:
- Prolonged filter lifetime corresponds to fewer filter changes4,10
- Low bleeding risk with expectedly fewer interventions needed5,7,8
- CiÄ¢¹½´«Ã½‘Ca Therapy protocol and products support a predictable workflow5,11
Think valueÄ¢¹½´«Ã½‘based.
Think CiÄ¢¹½´«Ã½‘Ca therapy.
Your question
How does CiÄ¢¹½´«Ã½‘Ca therapy support a valueÄ¢¹½´«Ã½‘basedÌýapproach and help to meet budget requirements?
Ìý
Ìý
Our answer
CiÄ¢¹½´«Ã½‘Ca therapy may improve your CKRT cost structure and total cost of ownership compared to systemic anticoagulation:5,14
- Fewer bleeding events, potentially resulting in a lower number of required blood transfusions5,15
- Less filter clotting leads to fewer treatment interruptions, reducing the workload and increasing the plannability of tasks4,5,10,11
- The smart CiÄ¢¹½´«Ã½‘Ca protocol enables efficient consumption of fluids by avoiding relevant predilution16,17
Think partner.
Think CiÄ¢¹½´«Ã½‘Ca therapy.
Your question
WhatÄ¢¹½´«Ã½™s the benefit for our hospitalÌýwhen switching to CiÄ¢¹½´«Ã½‘Ca therapy?
Ìý
Ìý
Ìý
Ìý
Our answer
Ä¢¹½´«Ã½ can be your trusted one-stop business partner:
- With our comprehensive CiÄ¢¹½´«Ã½‘Ca therapy portfolio of tailored products and services, we offer what you need for a reliable and effective CKRT4Ä¢¹½´«Ã½‘11Ìýfrom a single source.
- As the world's leading provider of products and services for individuals with kidney diseases, we are able to provide the full range of support required for switching to CiÄ¢¹½´«Ã½‘Ca therapy as well as for daily operation.
Related content
1ÌýTsujimoto H et al. Cochrane Database Syst Rev. 2020; 12(12):CD012467
2ÌýKDIGO Clinical Practice Guideline for Acute Kidney Injury., Kidney Int Suppl 2012; 2:1Ä¢¹½´«Ã½‘138
3ÌýBai M et al. Intensive Care Med 2015; 41:2098Ä¢¹½´«Ã½‘2110
4ÌýBianchi NA et al. Blood Purif 2020; 49:567Ä¢¹½´«Ã½‘575
5ÌýKalb R et al. Ther Apher Dial 2013; 17:202Ä¢¹½´«Ã½‘212
6ÌýMorgera et al. Crit Care Med 2009;37:2018Ä¢¹½´«Ã½‘2024
7ÌýSlowinski T et al. Crit Care 2015; 19:349
8ÌýLink A et al. Crit Care 2012; 16:R97
9ÌýHuguet M et al. Int J Artif Organs 2017; 40:676Ä¢¹½´«Ã½‘682
10ÌýHafner S et al. J Intensive Care 2015; 3:35
11ÌýHoullé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35Ä¢¹½´«Ã½‘41
12ÌýHetzel GR et al. Nephrol Dial Transpl 2011; 26:232Ä¢¹½´«Ã½‘239
13ÌýZarbock A et al. JAMA 2020; 324:1629Ä¢¹½´«Ã½‘1639
14ÌýDalhuisen A et al. Neth J Crit Care 2017; 25:122Ä¢¹½´«Ã½‘127
15ÌýKindgen-Milles D et al. Curr Opin Crit Care 2018; 24:450Ä¢¹½´«Ã½‘454
16ÌýHuang Z et al. Int J Artif Organs 2008, 31:525Ä¢¹½´«Ã½‘534
17ÌýNalesso F et al. J Clin Med 2020; 9:1529
UK-CITRATE-000012. Date of Preparation: March 2026.